TREC@TAMU Cancer Prevention Registry and Repository

NCT06826014 | Recruiting

• 1 other identifier: STUDY2024-0008
• Study Type: observational
• Target: 2,500
• Locations: 1 country
• Sites: 1

Brief Summary

This study collects health and genetic information to implement cancer prevention and treatment strategies.

Conditions

Cancer; Genetics; Disease; Diet; Lifestyle Factors

Keywords

cancer; genetics

Outcome Measures

Primary Outcomes (1)

• Frequency and nature of ADRs on the Naranjo Scale Questionnaire

  Measure the frequency and nature of adverse drug reactions by obtaining a complete medical history and physical examination and validating the patient's current concomitant medication list during the office visit. Patient medical information would be input into the ActX platform, which functions as a computable EHR medical record analysis, evaluation of polypharmacy status, and monitoring of ADRs using the Naranjo Scale will be conducted for the duration of the study.

  5 years

Secondary Outcomes (1)

• Self-reported Health status and any significant changes

  5 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

TREC@TAMU Registry will recruit as many participants as possible. The estimated enrollment in five years is expected to be 2500, but investigators will not limit recruitment if that number is exceeded.

You may qualify if:

• years of age and older, and,
• People participating in the Cancer Prevention and Research Institute of Texas (CPRIT) A coordinated cancer screening research program in Bryan and Navasota Family Medicine Clinics and,
• People with COPD, liver disease, cervical intraepithelial neoplasia (CIN) lesions, having had a colonoscopy or a low dose computed tomography (LDCT) lung scan or cervical exam in the last 12 months or scheduled for one, and,
• Able to give and comprehend the consent process, and,
• Able to consent to donate blood and urine samples, genetic material through buccal swabs for future research, and,
• Able to understand that their specimens, health record, and changes in health status will be followed for a five-year period and shared in deidentified form with the research community, and,
• All sexes and gender identities.

You may not qualify if:

• Declines to participate or interact with staff/share their medical status.
• A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning Individuals who are unable or unwilling to provide consent will be excluded

Sponsors & Collaborators

• Texas A&M University: lead

Study Sites (1)

Texas A&M Family Care

Bryan, Texas, 77802, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

blood, urine, saliva, and/or cheek cells.

MeSH Terms

Conditions

Neoplasms; Disease

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Kenneth S Ramos, MD

CONTACT

7136777740; kramos@tamu.edu

Rick Silva, PhD

CONTACT

(713) 677-7422; ricksilva@tamu.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 21, 2025
• First Posted: February 13, 2025
• Study Start: March 1, 2025
• Primary Completion (Estimated): November 1, 2030
• Study Completion (Estimated): November 1, 2030
• Last Updated: February 13, 2025

Record last verified: 2024-11

Locations

US (1)